Journal of Applied Physiology Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


J Appl Physiol (February 5, 2009). doi:10.1152/japplphysiol.90719.2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
106/4/1356    most recent
90719.2008v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yndestad, A.
Right arrow Articles by Andreassen, A. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yndestad, A.
Right arrow Articles by Andreassen, A. K.
Submitted on June 4, 2008
Revised on February 2, 2009
Accepted on February 2, 2009

Elevated levels of activin A in clinical and experimental pulmonary hypertension

Arne Yndestad1*, Karl-Otto Larsen2, Erik Oie3, Thor Ueland4, Camilla Smith3, Bente Halvorsen3, Ivar Sjaastad5, Ole Henning Skjonsberg2, Turid M. Pedersen3, Ole-Gunnar Anfinsen6, Jan Kristian Damås3, Geir Christensen2, Pal Aukrust4, and Arne K. Andreassen1

1 University of Oslo
2 Ulleval University Hospital
3 Rikshospitalet University Hospital
4 Rikshospitalet Medical Center
5 Ullevaal University Hospital
6 Rikshopitalet University Hospital

* To whom correspondence should be addressed. E-mail: arne.yndestad{at}rr-research.no.

Activin A, a member of the transforming growth factor (TGF)-{beta} superfamily, is involved in regulation of tissue remodeling and inflammation. Herein, we wanted to explore a role for activin A in pulmonary hypertension (PH). Circulating levels of activin A and its binding protein follistatin were measured in patients with PH (n=47) and control subjects (n=14). To investigate synthesis and localization of pulmonary activin A, we utilized an experimental model of hypoxia-induced PH. In mouse lungs we also explored signaling pathways that can be activated by activin A, such as phosphorylation of Smads which are mediators of TGF-{beta} signaling. Possible pathophysiological mechanisms initiated by activin A were explored by exposing pulmonary arterial smooth muscle cells in culture to this cytokine. Elevated levels of activin A and follistatin were found in patients with PH, and activin A levels were significantly related to mortality. Immunohistochemistry of lung autopsies from PH patients and lungs with experimental PH, localized activin A primarily to alveolar macrophages and bronchial epithelial cells. Mice with PH exhibited increased pulmonary levels of mRNA for activin A and follistatin in the lungs, and also elevated pulmonary levels of phosphorylated Smad2. Finally, we found that activin A increased proliferation and induced gene expression of endothelin-1 and plasminogen activator inhibitor-1 in pulmonary artery smooth muscle cells; mediators that could contribute to vascular remodeling. Our findings in both clinical and experimental studies suggest a role for activin A in the development of various types of PH.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1948 by the American Physiological Society.